GENEVA: The World Health Organization (WHO) advises “targeted vaccination” to combat Mpox rather than mass vaccination in affected areas, stating that controlling Mpox is easier than dealing with COVID-19.
WHO spokeswoman Margaret Harris emphasized the need for focused vaccination where the virus is actively spreading. The rapid spread of Mpox, particularly the new Clade 1b strain, which emerged last year and has a high transmission rate and mortality, especially among children, has raised global concern.
Harris highlighted the rise in Mpox cases in 2024 compared to 2023, with significant outbreaks in the eastern Democratic Republic of Congo, as well as Burundi, Rwanda, Uganda, and Kenya. She noted a higher fatality rate, around 3%, particularly among vulnerable groups like small children and displaced populations.
People with smallpox or HIV infections are at greater risk of severe Mpox and death. Although there is no specific treatment for Mpox, symptomatic care is effective.
Infected individuals typically develop skin rashes and may require fever-reducing and pain-relieving medications. Harris stressed the importance of medical treatment and isolation for those affected.
While smallpox vaccines are effective against Mpox, Harris recommends vaccination within four days of exposure for those at risk and for healthcare workers in the affected areas.
Furthermore, she assured that with good surveillance, contact tracing, and isolation measures, the virus can be controlled without lockdowns. Harris urged transparency in reporting cases, as this is crucial for controlling the outbreak and preventing it from becoming a pandemic.
